AVANIR Pharmaceuticals (NASDAQ:AVNR)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Results 1 - 20 of 39 : 1 2 Next »

Recs

0
Member Avatar a410traveler (< 20) Submitted: 8/10/2014 9:42:32 PM : Outperform Start Price: $5.43 AVNR Score: +4.12

Neudextra will drive profits in 2015 and 2016.

Recs

0
Member Avatar SubPrime (41.68) Submitted: 7/20/2014 7:40:36 PM : Outperform Start Price: $5.41 AVNR Score: +6.14

Products doing well in Europe should get FDA approval.

Recs

0
Member Avatar rogue66 (36.01) Submitted: 2/8/2014 12:44:07 PM : Outperform Start Price: $3.58 AVNR Score: +51.15

just a guess

Recs

0
Member Avatar habibnor (59.65) Submitted: 10/7/2013 2:43:16 PM : Outperform Start Price: $4.55 AVNR Score: +8.91

Obamacare !

Recs

0
Member Avatar fatmoneyrz (97.23) Submitted: 9/16/2013 10:01:29 AM : Outperform Start Price: $4.38 AVNR Score: +15.67

$30 dollar price target by Piper Jaffray. Sell off overblown, some significant upside here after Delaware court ruling.

Recs

0
Member Avatar jmontgomery86 (60.89) Submitted: 6/13/2013 8:49:04 PM : Outperform Start Price: $4.45 AVNR Score: +8.90

$8 PT on Nuedexta growth and European acceptance.

Recs

0
Member Avatar WakeUpInvestor (23.86) Submitted: 6/5/2013 5:19:03 PM : Outperform Start Price: $3.85 AVNR Score: +27.08

Lead product will be marketed in Europe this year.

Recs

0
Member Avatar headyinvestor (90.09) Submitted: 4/11/2012 8:43:27 AM : Underperform Start Price: $3.14 AVNR Score: -39.63

This company is trading at 50x revenue! Really!?

Recs

0
Member Avatar 1stMartian (< 20) Submitted: 12/6/2011 1:25:08 PM : Underperform Start Price: $2.50 AVNR Score: -74.39

Declining sales, declining cash flow, horrible ROI.

Recs

0
Member Avatar ramirogon (< 20) Submitted: 5/3/2011 7:23:43 PM : Outperform Start Price: $4.18 AVNR Score: -8.06

avnr

Recs

0
Member Avatar dgoldmeier (< 20) Submitted: 2/9/2011 5:23:42 PM : Outperform Start Price: $4.02 AVNR Score: -7.08

If sales on Nuxedta go well this company can hit a homerun. Well worth the risk.

Recs

0
Member Avatar bw64588 (< 20) Submitted: 2/8/2011 6:20:12 AM : Outperform Start Price: $4.18 AVNR Score: -12.04

AVNR is going to surprise everyone. I look for it to start running in March when we hear the first reports of sales figures for Neudexta.

Recs

1
Member Avatar peter1568 (< 20) Submitted: 11/25/2010 12:28:41 PM : Outperform Start Price: $4.30 AVNR Score: -32.28

avnr is a takeover target for big business, has approved drug, little or no debt and enough money for its production and distribution, I believe that large company that already has spoken waiting for the Q4 11/30/2010 to offer for the shares, the next month I see some of these big companies could get started talking to avnr to buy next year

Recs

0
Member Avatar upordownimup (< 20) Submitted: 11/16/2010 3:21:12 PM : Outperform Start Price: $4.60 AVNR Score: -43.03

New drug approved in hostile climate for new drugs. I think Abreva works like magic. Love their discovery method.

Recs

0
Member Avatar BadCopNoDonuts (< 20) Submitted: 11/1/2010 11:52:45 AM : Underperform Start Price: $5.10 AVNR Score: +53.70

I just bought March Puts for cheap. Kind of a no-brainer.

Recs

6
Member Avatar BioInvestor217 (< 20) Submitted: 9/29/2010 12:08:15 AM : Outperform Start Price: $3.32 AVNR Score: +0.55

Solid fundamentals and very good drug pipeline. See below for more info on their drug AVP-923 which is due for FDA review October 30th 2010. Expect to see major run-up and positive news. Conserative target before news: $4.25-$4.50. Clinical tests and trials look good, overall very good outlook.

"AVANIR is developing AVP-923 for use in PBA (also known as involuntary emotional expression disorder (IEED) and emotional lability) and diabetic peripheral neuropathic pain."

Recs

0
Member Avatar ebitdat (< 20) Submitted: 9/16/2010 8:16:26 PM : Outperform Start Price: $2.72 AVNR Score: +37.02

Expect a run-up to approval date

Recs

0
Member Avatar venkybt (< 20) Submitted: 7/13/2010 2:24:37 PM : Outperform Start Price: $3.51 AVNR Score: -16.47

As a new drug in the market with good safety profile always clicks,,,,,

Recs

0
Member Avatar Cosmo21 (< 20) Submitted: 6/12/2010 7:03:08 PM : Outperform Start Price: $2.75 AVNR Score: +30.68

Approval coming soon. Potential 9 $ stock.

Recs

0
Member Avatar LonWa (< 20) Submitted: 5/29/2010 10:46:01 AM : Outperform Start Price: $2.38 AVNR Score: +59.86

Looks good but will hold off buying for now, think it will go down a little more before it starts to move up.

Results 1 - 20 of 39 : 1 2 Next »

Featured Broker Partners


Advertisement